|
Nereus Pharmaceuticals is a pharmaceutical company focused on the development of natural products from marine microbial and other natural sources into small molecule human therapeutics. The major disease area addressed by Nereus is cancer. As of 2008, Nereus has no marketed products and its operating funds have been secured through several rounds of preferred stock sales.〔 ==Drug discovery== Until 2004, Nereus used methods licensed from the University of California, San Diego to retrieve and cultivate marine microorganisms, particularly bacteria in the Actinobacteria class and organisms belonging to Kingdom Fungi.〔 Since 2004, the company has focused on commercializing identified bioactive natural products.〔 As of mid-2007, two compounds were being examined in Phase I clinical trials: NPI-2358 and NPI-0052.〔 * Plinabulin (NPI-2358) is a halimide derivative, halimide itself having been isolated from a member of genus ''Aspergillus''.〔 This compound appears to selectively disrupt tumour vasculature through interaction with microtubules.〔 * NPI-1342 (Acanthoic Acid analog, NPI-1302a-3) is a plant derived orally active small molecule that targets the NF_kB transcript factor pathway. It is significantly active against cancer and inflammatory diseases and is being developed for clinical testing in multiple myeloma and glioblastoma. * Salinosporamide A (NPI-0052) is a natural product of ''Salinispora tropica'', a member of the bacterial family ''Micromonosporaceae'' that was first isolated in 2002 and taxonomically identified genetically in 2005. NPI-0052 acts as a proteasome inhibitor.〔 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Nereus Pharmaceuticals」の詳細全文を読む スポンサード リンク
|